Rahul Nachnani
Penn State University
Objective: Cannabigerol (CBG), is the precursor molecule to most cannabinoids including delta 9-tetrahydrocannabinol (THC) and cannabidiol (CBD). Non-psychoactive cannabinoids, such as CBD and CBG, show promise for attenuating substance seeking behavior along with anti-inflammatory, analgesic, and anti-epileptic activity. CBG, in particular, displays potency at distinct non-cannabinoid receptors: alpha-2 adrenoceptors, PPARα/ɣ, and serotonin 5-HT1A receptor. We propose CBG as a novel therapeutic in the cannabinoid class of drugs with potential for pain, inflammation, and psychiatric disorders (substance abuse, ADHD, etc.).